Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
ADMA Biologics, Inc. ADMA
$4.15
+$0.19 (4.67%)
На 18:00, 12 мая 2023
+26.51%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
877883518.00000000
-
week52high
3.98
-
week52low
1.43
-
Revenue
154079692
-
P/E TTM
-7
-
Beta
0.91003400
-
EPS
-0.34000000
-
Last Dividend
0.00000000
-
Next Earnings Date
10 мая 2023 г. в 20:00
Описание компании
ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. The company also develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, sales agents, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| HC Wainwright & Co. | Buy | Buy | 25 июл 2022 г. |
| Raymond James | Strong Buy | Outperform | 11 ноя 2021 г. |
| Cantor Fitzgerald | Overweight | 09 ноя 2021 г. | |
| Raymond James | Outperform | Outperform | 26 окт 2021 г. |
| HC Wainwright & Co. | Buy | Buy | 12 авг 2021 г. |
| Mizuho | Buy | 13 окт 2022 г. | |
| Mizuho | Buy | Buy | 10 ноя 2022 г. |
| HC Wainwright & Co. | Buy | Buy | 03 янв 2023 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| LENZ BRIAN | D | 920603 | 114222 | 04 янв 2023 г. |
| Grossman Adam S | D | 2036841 | 166867 | 04 янв 2023 г. |
| Grossman Adam S | A | 1143426 | 14982 | 09 дек 2022 г. |
| Grossman Adam S | A | 2203708 | 14983 | 09 дек 2022 г. |
| LENZ BRIAN | A | 1034825 | 6993 | 09 дек 2022 г. |
| Grossman Adam S | D | 2188725 | 101315 | 30 сент 2022 г. |
| LENZ BRIAN | D | 1027832 | 73678 | 30 сент 2022 г. |
| Grossman Adam S | D | 2290040 | 70004 | 11 мая 2022 г. |
| LENZ BRIAN | D | 1101510 | 51965 | 11 мая 2022 г. |
| Grossman Adam S | D | 2360044 | 50539 | 23 мар 2022 г. |
Новостная лента
Is ADMA Biologics (ADMA) Stock Outpacing Its Medical Peers This Year?
Zacks Investment Research
12 мая 2023 г. в 11:25
Here is how Adma Biologics (ADMA) and Swedish Orphan Biovitrum (BIOVF) have performed compared to their sector so far this year.
Adma Biologics (ADMA) Reports Q1 Loss, Tops Revenue Estimates
Zacks Investment Research
10 мая 2023 г. в 18:59
Adma Biologics (ADMA) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to loss of $0.10 per share a year ago.
ADMA Biologics to Report First Quarter 2023 Financial Results on May 10, 2023
GlobeNewsWire
03 мая 2023 г. в 07:00
RAMSEY, N.J. and BOCA RATON, Fla.
ADMA Biologics Announces Q4 And FY 2022 Results
Pulse2
24 мар 2023 г. в 14:01
ADMA Biologics (NASDAQ: ADMA) has reported its Q4 and full-year 2022 financial results. These are the details.
ADMA Biologics, Inc. (ADMA) Q4 2022 Earnings Call Transcript
Seeking Alpha
23 мар 2023 г. в 22:10
ADMA Biologics, Inc. (NASDAQ:ADMA ) Q4 2022 Earnings Conference Call March 23, 2023 4:30 PM ET Company Participants Skyler Bloom - Senior Director of Business Development & Corporate Strategy Adam Grossman - Co-Founder, President, CEO & Director Brian Lenz - EVP, CFO & GM, ADMA BioCenters Conference Call Participants Anthony Petrone - Mizuho Securities Elliot Wilbur - Raymond James & Associates Kristen Kluska - Cantor Fitzgerald & Co. Operator Good afternoon, and welcome to the ADMA Biologics Fourth Quarter and Full Year 2022 Financial Results and Corporate Update Conference Call on Thursday, March 23, 2023. [Operator Instructions].